Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FNTA | P49354 | 17/20 | 0.83 |
| ▸ | FNTB | P49356 | 17/20 | 0.83 |
| ▸ | PGGT1B | P53609 | 3/20 | 0.49 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4372438 | 0.91 | FNTA (1.00) | FNTAFNTBPGGT1BCYP3A4 | |
| SCHEMBL4373656 | 0.89 | FNTA (0.82) | FNTAFNTBPGGT1B | |
| SCHEMBL4374148 | 0.85 | FNTA (0.63) | FNTAFNTBPGGT1BCYP3A4 | |
| SCHEMBL4370593 | 0.84 | FNTA (0.75) | FNTAFNTBPGGT1BCYP3A4 | |
| SCHEMBL4375776 | 0.78 | FNTA (0.65) | FNTAFNTBPGGT1B | |
| SCHEMBL6841546 | 0.77 | FNTA (0.76) | FNTAFNTBPGGT1BCYP3A4 | |
| SCHEMBL5513838 | 0.75 | FNTA (0.60) | FNTAFNTBPGGT1B | |
| SCHEMBL4382829 | 0.74 | FNTA (0.62) | FNTAFNTBPGGT1B | |
| SCHEMBL4373759 | 0.74 | FNTA (0.81) | FNTAFNTBPGGT1B | |
| SCHEMBL4373631 | 0.74 | FNTA (0.59) | FNTAFNTB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1339709-B1 | FARNESYL TRANSFERASE INHIBITING BENZOHETEROCYCLIC DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2009-06-24 | — | — | EP | disclosed |
| US-7153958-B2 | Farnesyl transferase inhibiting benzoheterocyclic derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-12-26 | — | — | US | disclosed |
| US-20040034218-A1 | Farnesyl transferase inhibiting benzoheterocyclic derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 2004-02-19 | — | — | US | disclosed |
| EP-1339709-A1 | FARNESYL TRANSFERASE INHIBITING BENZOHETEROCYCLIC DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 2003-09-03 | — | — | EP | disclosed |
| WO-2002042296-A1 | FARNESYL TRANSFERASE INHIBITING BENZOHETEROCYCLIC DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 2002-05-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040034218-A1 | Farnesyl transferase inhibiting benzoheterocyclic derivatives | FNTA, FNTB, RCE1 | FNTA 1/4885FNTB 2/4885PGGT1B 32/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.